Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation

Medtronic plc (NYSE:MDT) today announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a unique, phased clinical program studying renal denervation in uncontrolled hypertension. This announcement follows investigational device exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The program will begin with two global studies designed to address the confounding factors encountered in the SYMPLICITY HTN-3 clinical trial, including medication, patient population and procedural variability, to ensure the clinical potential of the therapy is evaluated.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news